Teva Pharmaceutical Industries Limited (TLV:TEVA)
13,330
-590 (-4.24%)
Nov 19, 2026, 5:27 PM IST
Teva Pharmaceutical Industries Employees
As of December 31, 2025, Teva Pharmaceutical Industries had 32,842 total employees, including 31,173 full-time and 1,669 part-time employees. The number of employees decreased by 2,844 or 7.97% compared to the previous year.
Employees
32,842
Change (1Y)
-2,844
Growth (1Y)
-7.97%
Revenue / Employee
1.65M ILS
Profits / Employee
48.49K ILS
Market Cap
154.91B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 32,842 | -2,844 | -7.97% | 31,173 | 1,669 |
| Jun 30, 2025 | 37,000 | 0 | - | 37,000 | 0 |
| Mar 31, 2025 | 37,000 | 528 | 1.45% | 37,000 | 0 |
| Dec 31, 2024 | 35,686 | -786 | -2.16% | 33,892 | 1,794 |
| Sep 30, 2024 | 37,000 | 528 | 1.45% | 37,000 | 0 |
| Dec 31, 2023 | 36,472 | 1,347 | 3.83% | 35,001 | 1,471 |
| Dec 31, 2022 | 35,125 | -854 | -2.37% | 34,004 | 1,121 |
| Dec 31, 2021 | 35,979 | -2,393 | -6.24% | 34,713 | 1,266 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Amal Holdings A.D. | 30,248 |
| Danel (Adir Yeoshua) | 4,288 |
| Novolog (Pharm-Up 1966) | 916 |
| Kamada | 462 |
| Rafa Laboratories | 257 |
| Bait Bakfar | 244 |
| Ilex Medical | 181 |
| SofWave Medical | 151 |
Teva Pharmaceutical Industries News
- 11 hours ago - Teva price target raised to $50 from $47 at Barclays - TheFly
- 23 hours ago - Teva chief medical officer Eric Hughes to leave company - TheFly
- 23 hours ago - Teva Announces R&D Leadership Transition; Eric Hughes to Depart the Company - GlobeNewsWire
- 2 days ago - Teva price target raised to $50 from $42 at Argus - TheFly
- 3 days ago - Teva announces FDA approval of Igalmi sublingual film for at-home use - TheFly
- 7 days ago - Teva price target raised to $56 from $44 at Piper Sandler - TheFly
- 8 days ago - Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030 - GlobeNewsWire
- 9 days ago - Alvotech initiated with a Buy at Jefferies - TheFly